News   /   Russia

Russia completes early trials of second potential COVID-19 vaccine: Interfax

A handout photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (COVID-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia August 6, 2020. (By Reuters)

Siberia's Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.

Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week.

Human trials of the second potential COVID-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.

"Today ... the final group of 20 volunteers was released from hospital," said in a statement. "All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good."

Results are due to be published on September 30, Interfax said.

'India mulling Russian offer for vaccine trial, manufacturing'

An Indian government official said on Tuesday, that India has received an offer from Russia to conduct a trial and manufacture its "Sputnik-V" COVID-19 vaccine, with several Indian companies currently studying the proposal.

"The government of India attaches great importance to this offer of partnership from a friend," said V. K. Paul, member of the Indian federal government think-tank NITI Aayog.

The outcome of discussions on the offer were expected soon, he added.

(Source: Reuters)


Press TV’s website can also be accessed at the following alternate addresses:

www.presstv.co.uk

SHARE THIS ARTICLE
Press TV News Roku